EN | RU
EN | RU

Help Support

Back

Golimumab shows good retention rates in patients having axial spondyloarthritis and rheumatoid arthritis

Golimumab shows good retention rates in patients having axial spondyloarthritis and rheumatoid arthritis Golimumab shows good retention rates in patients having axial spondyloarthritis and rheumatoid arthritis
Golimumab shows good retention rates in patients having axial spondyloarthritis and rheumatoid arthritis Golimumab shows good retention rates in patients having axial spondyloarthritis and rheumatoid arthritis

What's new?

Golimumab displayed good retention rates at two years when used for treating people with axial spondyloarthritis and rheumatoid arthritis.

In a real-world setting, golimumab is effective for managing rheumatoid arthritis and axial spondyloarthritis individuals with good retention rates at two years. This real-world study aimed to explore the retention rate of golimumab in individuals having rheumatoid arthritis and axial spondyloarthritis that had received/were receiving golimumab as their 1st  or 2nd  biological drug for at least three months.

Data on drug continuation and disease activity, and  demographic and clinical data were collected. Participants were segregated as biologic-naive and biologic-experienced. The study incorporated 60 rheumatoid arthritis and 269 axial spondyloarthritis participants. At 24 months, the retention rate for rheumatoid arthritis patients (biologic-naive and biologic-experienced) and axial spondyloarthritis patients (Anti TNF-naive and -experienced) is illustrated in Table 1:


No vital differences in retention rates were witnessed between the groups for either disease. Thus, golimumab is an effective therapeutic agent with good retention rates for managing axial spondyloarthritis and rheumatoid arthritis patients.

Source:

Immunotherapy

Article:

GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey

Authors:

Servet Akar et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: